CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.00-20.00%
OTC PK
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 221.04% | -37.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 221.04% | -37.56% | |||
| Operating Income | -221.04% | 37.56% | |||
| Income Before Tax | -151.42% | 14.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -151.42% | 14.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -151.42% | 14.47% | |||
| EBIT | -221.04% | 37.56% | |||
| EBITDA | -400.90% | 52.25% | |||
| EPS Basic | 57.14% | 36.36% | |||
| Normalized Basic EPS | 55.56% | 35.71% | |||
| EPS Diluted | 57.14% | 36.36% | |||
| Normalized Diluted EPS | 55.56% | 35.71% | |||
| Average Basic Shares Outstanding | 501.38% | 32.72% | |||
| Average Diluted Shares Outstanding | 501.38% | 32.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||